Table 2 Factors associated with death among patients with COVID-19 receiving lopinavir-ritonavir (n = 125).
From: High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
Characteristic | N | Deaths n (%) | Unadjusted OR (95% CI) | Univariate p value | Adjusted OR (95% CI) | Multivariate p value |
|---|---|---|---|---|---|---|
Agea ( years) | < 0.001 | – | ||||
< 65 | 64 | 3 (4.7) | ||||
≥ 65 | 61 | 23 (38) | 12 (3.5–44) | |||
Sex | 0.819 | 0.980 | ||||
Men | 60 | 13 (22) | 1.1 (0.5–2.6) | 1.0 (0.4–2.9) | ||
Women | 65 | 13 (20) | ||||
Charlson index | < 0.001 | < 0.001 | ||||
0–2 | 62 | 1 (1.6) | Reference | |||
3–4 | 37 | 9 (24) | 19.6 (2.4–162) | 18 (2.2–151) | 0.008 | |
≥ 5 | 26 | 16 (62) | 98 (11–820) | 85 (10–731) | < 0.001 | |
Drug-drug interactions | 0.010 | 0.383 | ||||
Not major | 92 | 14 (15) | 3.2 (1.3–7.9) | |||
Major | 33 | 12 (36) | 1.6 (0.6–4.8) | |||
Management | 0.584 | - | ||||
Infectious diseases unit | 54 | 10 (19) | ||||
Other units | 71 | 16 (23) | 1.3 (0.5–3.1) | |||
